The JP Morgan Healthcare Conference is wrapping up after an eventful and interesting week. Much of the commentary was around the incoming administration set for inauguration on Monday (January 20th). A last-minute move by the Biden Administration to add Novo Nordisk to the Medicare price negotiations list certainly caused some action in the markets.
Standard Bio Tools said it expects Q4 revenues of $46.5M up 65% from the previous year’s Q4
Sera Prognostics presents data that shows PreTRM proteomic blood test reduced hospital admissions to the NICU for newborns by 22% and 8% fewer days in the hospital for babies admitted to the NICU
Novo Nordisk had its premier drugs added to the forced price negotiations list for Medicare by the Biden administration in a last-minute announcement
OraSure Technologies announces launch of research use only blood based proteomics product in 2025
Geneoscopy’s partnership with Laboratory Corporation of America will help it roll out commercial access of its ColoSense test following FDA approval last year
Comments